LeMaitre Vascular heads into its May 7 Q1 earnings report with options traders pushing defensive positioning to the most extreme level of the past year.
The put/call ratio has climbed to 2.91 — a 52-week high — running well above its 20-day average of 2.41. That's more than one standard deviation above the norm, marking the most heavily put-skewed options market the stock has seen in at least twelve months. The stock itself has been broadly resilient, up roughly 3% over the past month to $112.00, though it gave back a fraction of that on the week. The combination of price stability and rising put demand points to investors buying protection rather than expressing outright bearishness.
Short interest adds a secondary note of caution. At 6.1% of free float, it is a genuine level worth watching, and it has risen 14% over the past month — the bulk of that jump occurring after early April. Days to cover run close to eight, suggesting any rapid unwind would take time. That said, the borrow market remains loose: cost to borrow is just 0.53%, even after a roughly 20% rise over the past month, and availability is well above levels that would signal squeeze pressure. Short interest here looks like a measured directional bet rather than an aggressive squeeze setup.
The analyst debate into the print is split between confidence in the business model and concern about concentration risk. Bulls point to LeMaitre's diversified vascular device portfolio and its track record of pursuing acquisitions, with Roth Capital and Citizens both carrying Buy-equivalent ratings and targets north of $115. Bears flag reliance on international revenue and potential vulnerability to macro headwinds, with Wells Fargo sitting at Equal-Weight. The most recent round of target upgrades all arrived in late February following the prior quarter's results — none of the changes are recent enough to shift the current narrative. The consensus mean target of $111.22 is essentially in line with the current price, suggesting the Street sees the stock as fairly valued at these levels. Note that the analyst consensus data is over a month old and may not fully reflect post-tariff sentiment.
Ownership data offers one notable detail heading in. Founder and CEO George LeMaitre sold nearly 56,000 shares in early March at around $107.80, a transaction worth over $6 million. The President also sold across late February and March. Both followed the prior earnings pop — the stock fell 5.5% on the day after the February Q4 report — and the pattern of executive selling into strength is a thread the May print will either validate or complicate. Goldman Sachs Asset Management added 212,000 shares in Q1, a meaningful accumulation that partially offsets the insider supply narrative.
The May 7 report is therefore a test of whether LeMaitre's organic growth and acquisition pipeline can justify a 37x earnings multiple at a moment when the put market is more defensive than it has been all year.
See the live data behind this article on ORTEX.
Open LMAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
